menu
    • menu
    [{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Maruho"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AOBiome Therapeutics

    Menu

    AOBiome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Maruho

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AOB Pharma Enters License Agreement for Topical Biologic B244 in Japan

                            Details : The agreement aims to develop AOB's topical biologic B244, preparing for global Phase 3 trials, a therapeutic for dermatological conditions like Atopic Dermatitis and pruritus.

                            Product Name : B244

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            May 01, 2024

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Maruho

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

                            Details : B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. It has shown clinical significance for atopic dermatitis and associated prurit...

                            Product Name : B244

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 04, 2023

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherape...

                            Details : Company’s lead product candidate, B244, a live topical biotherapeutic, subject Phase 2b trial for Treatment of Pruritus associated with Atopic Dermatitis successfully completes its recruitment goal.

                            Product Name : B244

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            November 16, 2021

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New 30 Patient Study Of AOBiome's New Shelf-Stable Formulation Of Its Ammonia Oxidizing Bacteria (AOB) Shows R...

                            Details : A total of 30 subjects used a cream containing metabolically inactive AOB twice a day for 2 weeks. Continuing the historically strong safety profile of applied AOB, the cream formulation was well-tolerated by the subjects.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            August 17, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AOBiome Reports Successful Clinical Trials in Pruritus Associated with Atopic Dermatitis

                            Details : The adult trial was a double blind, placebo controlled, multicenter, Phase 2a study of B244, a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria, delivered as a topical spray twice daily for 28 days.

                            Product Name : B244

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth